MYD88 and neoplasm: Our findings demonstrate that the MyD88-dependent maturation of TiDCs (including cDCs and pDCs) coupled with their migration to dLNs, plays a central role in the induction of tumor-specific immunity as elicited by the intratumoral administration of LTX-315.